Pliant End Period Cash Flow from 2010 to 2024

PLRX Stock  USD 13.30  0.70  5.00%   
Pliant Therapeutics End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow will likely drop to about 55.3 M in 2024. During the period from 2010 to 2024, Pliant Therapeutics End Period Cash Flow regression line of annual values had r-squared of  0.59 and arithmetic mean of  29,134,537. View All Fundamentals
 
End Period Cash Flow  
First Reported
2018-12-31
Previous Quarter
80.4 M
Current Value
81.1 M
Quarterly Volatility
38 M
 
Covid
Check Pliant Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pliant Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 1.3 M, Net Interest Income of 20.2 M or Interest Income of 21.5 M, as well as many indicators such as Price To Sales Ratio of 707, Dividend Yield of 0.0 or PTB Ratio of 2.36. Pliant financial statements analysis is a perfect complement when working with Pliant Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Pliant Therapeutics Correlation against competitors.
For more information on how to buy Pliant Stock please use our How to Invest in Pliant Therapeutics guide.

Latest Pliant Therapeutics' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Pliant Therapeutics over the last few years. It is Pliant Therapeutics' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pliant Therapeutics' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

Pliant End Period Cash Flow Regression Statistics

Arithmetic Mean29,134,537
Geometric Mean14,119,727
Coefficient Of Variation101.03
Mean Deviation26,542,440
Median4,251,000
Standard Deviation29,434,873
Sample Variance866.4T
Range81.6M
R-Value0.77
Mean Square Error381.7T
R-Squared0.59
Significance0.0008
Slope5,059,666
Total Sum of Squares12129.8T

Pliant End Period Cash Flow History

202455.3 M
202364.7 M
202233.7 M
202151.7 M
202050.9 M
201985.8 M
201860.9 M

About Pliant Therapeutics Financial Statements

Pliant Therapeutics investors use historical fundamental indicators, such as Pliant Therapeutics' End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pliant Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow64.7 M55.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Pliant Stock Analysis

When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.